Role of endothelin in regulation of resistance, fluid-exchange, and capacitance functions of the systemic circulation

Canadian Journal of Physiology and Pharmacology

Volumn 81, Issue 6, 2003, Pages 522-532

  McNeill, J Robert ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Capacitance; Endothelin; Fluid exchange; Hemodynamics; Resistance

Indexed keywords

ANGIOTENSIN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR AGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; VASOPRESSIN;

BLOOD PRESSURE; BLOOD VESSEL CAPACITANCE; DEPRESSOR RESPONSE; HEMODYNAMICS; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; MESENTERIC ARTERY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL ARTERY; REVIEW; SYSTEMIC CIRCULATION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VENOCONSTRICTION;

ANIMALS; BLOOD CIRCULATION; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELINS; HUMANS; RECEPTORS, ENDOTHELIN; VASCULAR CAPACITANCE; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0038300801     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y03-016     Document Type: Review

References (65)

1. Ahlborg, G., Weitzberg, E., and Lundberg, J.M. 1995. Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans. J. Appl. Physiol. 79: 141-5.
2. Balakrishnan, S., Wang, H.D., Gopalakrishnan, V., Wilson, T.W., and McNeill, J.R. 1996. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension, 28: 806-809.
3. Balakrishnan, S., Tatchum-Talom, R., and McNeill, J.R. 1998. Radiotelemetric versus externalized catheter monitoring of blood pressure: Effect of vasopressin in spontaneous hypertension. J. Pharmacol. Toxicol. Methods, 40: 87-93.
4. Bazil, M.K., Krulan, C., and Webb, R.L. 1993. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 22: 897-905.
5. B antagonist, TAK-044, on blood pressure and renal excretory function after unclipping of conscious one-kidney-one-clip hypertensive rats. J. Hypertens. 19: 659-65.
6. Berne, R.M., and Levy, M.N. 1972. Cardiovascular physiology. 2nd ed. The C.V. Mosby Co., St. Louis.
7. Berthold, H., Munter, K., Just, A., Kirchheim, H.R., and Ehmke, H. 1999. Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog. Am. J. Physiol. 276: F417-F424.
8. Blouin, A., Molez, S., Pham, D., Ayach, B., Dussault, P., Escher, E., Jeng, A.Y., and Battistini, B. 2000. A novel procedure for daily measurements of hemodynamical, hematological, and biochemical parameters in conscious unrestrained rats. J. Pharmacol. Toxicol. Methods, 44: 489-505.
9. Cardillo, C., Kilcoyne, C.M., Waclawiw, M., Cannon, R.O., 3rd, and Panza, J.A. 1999. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension, 33: 753-758.
10. Chen, L., McNeill, J.R., Wilson, T.W., and Gopalakrishnan, V. 1995a. Differential effects of phosphoramidon on contractile responses to angiotensin II in rat blood vessels. Br. J. Pharmacol. 114: 1599-1604.
11. Chen, L., McNeill, J.R., Wilson, TW., and Gopalakrishnan, V. 1995b. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin. Hypertension, 26: 83-88.
12. Douglas, S.A., Gellai, M., Ezekiel, M., and Ohlstein, E.H. 1994. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J. Hypertens. 12: 561-567.
13. Douglas, S.A., Gellai, M., Ezekiel, M., Feuerstein, G.Z., Elliott, J.D., and Ohlstein, E.H. 1995. Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension, 25: 818-822.
14. Ekelund, U., Albert, U., Edvinsson, L., and Mellander, S. 1993. Invivo effects of endothelin-1 and ETa receptor blockade on arterial, venous and capillary functions in skeletal muscle. Acta Physiol. Scand. 148: 273-283.
15. B-receptor stimulation on arterial, venous and capillary functions in cat skeletal muscle. Br. J. Pharmacol. 112: 887-894.
16. Emori, T., Hirata, Y., Ohta, K., Kanno, K., Eguchi, S., Imai, T., Shichiri, M., and Marumo, F. 1991. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension, 18: 165-170.
17. Fink, G.D., Johnson, R.J., and Galligan, J.J. 2000. Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension. Hypertension, 35: 464-469.
18. Frelin, C., and Guedin, D. 1994. Why are circulating concentrations of endothelin-1 so low? Cardiovasc. Res. 28: 1613-1622.
19. Gardiner, S.M., Compton, A.M., and Bennett, T. 1990. Regional hemodynamic effects of endothelin-2 and sarafotoxin-S6b in conscious rats. Am. J. Physiol. 258: R912-R917.
20. B-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br. J. Pharmacol. 112: 823-830.
21. Gardiner, S.M., Kemp, P.A., March, J.E., Bennett, T., Davenport, A.P., and Edvinsson, L. 1994b. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br. J. Pharmacol. 112: 477-486.
22. Gardiner, S.M., March, J.E., Kemp, P.A., Mullins, J.J., and Bennett, T. 1995. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br. J. Pharmacol. 116: 2237-2244.
23. Gardiner, S.M., March, J.E., Kemp, P.A., and Bennett, T. 2000. Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats. Br. J. Pharmacol. 131: 1732-1738.
24. A receptor antagonist, SB 234551, on the cardiovascular responses to endotoxaemia in conscious rats. Br. J. Pharmacol. 133: 1371-1377.
25. Gellai, M., Fletcher, T., Pullen, M., and Nambi, P. 1996. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am. J. Physiol. 271: R254-R261.
26. Greenway, C.V., and Lautt, W.W. 1986. Blood volume the venous system preload and cardiac output. Can. J. Physiol. Pharmacol. 64: 383-387.
27. Hand, M.F., Haynes, W.G., and Webb, D.J. 2001. Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure. Nephrol. Dial Transplant, 16: 295-301.
28. Haynes, W.G., and Webb, D.J. 1993. Venoconstriction to endothelin-1 in humans: role of calcium and potassium channels. Am. J. Physiol. 265: H1676-H1681.
29. Haynes, W.G., Hand, M.F., Johnstone, H.A., Padfield, P.L., and Webb, D.J. 1994. Direct and sympathetically mediated veno-constriction in essential hypertension. Enhanced responses to endothelin-1. J. Clin. Invest. 94: 1359-1364.
30. Haynes, W.G., Moffat, S., and Webb, D.J. 1995. An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. Br. J. Clin. Pharmacol. 40: 307-311.
31. Haynes, W.G., Ferro, C.J., O'Kane, K.P., Somerville, D., Lomax, C.C., and Webb, D.J. 1996. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation, 93: 1860-1870.
32. Hughes, A.D., Thom, S.A., Woodall, N., Schachter, M., Hair, W.M., Martin, G.N., and Sever, P.S. 1989. Human vascular responses to endothelin-1: observations in vivo and in vitro. J. Cardiovasc. Pharmacol. 13(Suppl. 5): S225-S228.
33. Imai, T., Hirata, Y., Emori, T., Yanagisawa, M., Masaki, T., and Marumo, F. 1992. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension, 19: 753-757.
34. A/B endothelin receptor antagonist on venomotor tone in deoxycorticosterone-salt hypertension. J. Hypertens. 19: 431-440.
35. Lemmer, B., Witte, K., Makabe, T., Ganten, D., and Mattes, A. 1994. Effects of enalaprilat on circadian profiles in blood pressure and heart rate of spontaneously and transgenic hypertensive rats. J. Cardiovasc. Pharmacol. 23: 311-314.
36. MacDonald, M.B., Laing, G.P., Wilson, M.P., and Wilson, T.W. 1999. Prevalence and predictors of white-coat response in patients with treated hypertension. CMAJ, 161: 265-269.
37. Martin, D.S., and McNeill, J.R. 1990. Arginine vasopressin increases aparent whole body capacity in anesthetized cats. Am. J. Physiol. 258: H722-H728.
38. Martin, D.S., and McNeill, J.R. 1991. Whole body vascular capacitance response to vasopressin is mediated by autonomic function. Am. J. Physiol. 261: H493-H499.
39. Miyauchi, T., and Masaki, T. 1999. Pathophysiology of endothelin in the cardiovascular system. Annu. Rev. Physiol. 61: 391-415.
40. Münter, K., Ehmke, H., and Kirchengast, H. 1999. Maintenance of blood pressure in normotensive dogs by endothelin. Am. J. Physiol. 276: H1022-H1027.
41. A receptor antagonist, J-105859. J. Hypertens. 18: 1815-1823.
42. Palacios, B., Lim, S.L., and Pang, C.C.Y. 1997a. Effects of endothelin-1 on arterial and venous resistances in anaesthetized rats. Eur. J. Pharmacol. 327: 183-188.
43. Palacios, B., Lim, S.L., and Pang, C.C.Y. 1997b. Subtypes of endothelin receptors that mediate venous effects of endothelin-1 in anaesthetized rats. Br. J. Pharmacol. 122: 993-998.
44. B receptors counteract venoconstrictor effects of endothelin-1 in anesthetized rats. Life Sci. 63: 1239-1249.
45. Pang, C.C.Y. 1994. The effects of drugs on the venous system. R.G. Landes Company, Austin, Tex.
46. Parker, J.D., Thiessen, J.J., Reilly, R., Tong, J.H., Stewart, D.J., and Pandey, A.S. 1999. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J. Pharmacol. Exp. Ther. 289: 261-265.
47. Pernow, J., Hemsen, A., Lundberg, J.M., Nowak, J., and Kaijser, L. 1991. Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiol. Scand. 141: 319-324.
48. Pernow, J., Kaijser, L., Lundberg, J.M., and Ahlborg, G. 1996. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation, 94: 2077-2082.
49. Rothe, C.F. 1983. Venous system: physiology of the capacitance vessels. In Handbook of physiology: the cardiovascular system. Edited by J.T. Shepherd and F.M. Abboud. Waverly Press Inc., Baltimore, Md. pp. 397-452.
50. Rothe, C.F., and Maass-Moreno, R. 2000. Active and passive liver microvascular responses from angiotensin, endothelin, norepinephrine, and vasopressin. Am. J. Physiol. 279: H1147-H1156.
51. Schiffrin, E.L. 1995a. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension, 25: 1135-1143.
52. Schiffrin, E.L. 1995b. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension, 25: 1135-1143.
53. A receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br. J. Pharmacol. 134: 648-654.
54. Strachan, F.E., Haynes, W.G., and Webb, D.J. 1995. Endothelium-dependent modulation of venoconstriction to sarafotoxin S6c in human veins in vivo. J. Cardiovasc. Pharmacol. 26(Suppl. 3): S180-S182.
55. Strachan, F.E., Spratt, J.C., Wilkinson, I.B., Johnston, N.R., Gray, G.A., and Webb, D.J. 1999. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension, 33: 581-585.
56. Strachan, F.E., Crockett, T.R., Mills, N.L., Gray, G.A., and Webb, D.J. 2000. Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin s6c, in human resistance and capacitance vessels in vivo. Br. J. Clin. Pharmacol. 50: 27-30.
57. Takai, K., Ito, H., Sahashi, T., Wada, H., Segawa, T., and Hirakawa, S. 1992. Differing actions of endothelin-1 on canine systemic resistance and capacitance vessels. Jpn. Circ. J. 56: 847-854.
58. Tomobe, Y., Yanagisawa, M., Fujimori, A., Masaki, T., and Goto, K. 1993. Arginine-vasopressin increases the release of ET-1 into perfusate of rat mesenteric artery. Biochem. Biophys. Res. Commun. 191: 654-661.
59. Torres Jimenez, J.I., Martinez Pena, E., Adrian, N., Galicia Paredes, M.A., Britt, M.J., and Cordero Guevara, J. 2001. [Variations in the prevalence and patient profile of white-coat syndrome, according to its definition using self-measurement of blood pressure at home]. Aten Primaria, 28: 234-240.
60. Wagner, O.F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P.J., Schneider, B., Waldhausl, W., and Binder, B.R. 1992. Polar secretion of endothelin-1 by cultured endothelial cells. J. Biol. Chem. 267: 16 066-16 068.
61. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London), 332: 411-415.
62. Yu, M., Gopalakrishnan, V., and McNeill, J.R. 1998. Hemodynamic Effect of a selective endothelin-a receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. J. Cardiovasc. Pharmacol. 31(Suppl. 1): S262-S264.
63. Yu, M., Gopalakrishnan, V., and McNeill, J.R. 1999. Total peripheral conductance mediates antihypertensive effect of nonpeptide mixed endothelin receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. Am. J. Hypertens. 12: 845-848.
64. Yu, M., Gopalakrishnan, V., and McNeill, J.R. 2001a. Role of endothelin and vasopressin in DOCA-salt hypertension. Br. J. Pharmacol. 132: 1447-1454.
65. Yu, M., Gopalakrishnan, V., Wilson, T.W., and McNeill, J.R. 2001b. Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension. Am. J. Physiol. 281: H2511-H2517.